4.7 Article

Small mitochondrial-targeted RNAs modulate endogenous mitochondrial protein expression in vivo

Journal

NEUROBIOLOGY OF DISEASE
Volume 69, Issue -, Pages 15-22

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2014.04.017

Keywords

Mitochondrial disorders; Translation inhibitors; Non-coding small chimeric RNA; Mitochondrial encoded proteins

Categories

Funding

  1. National Institutes of Health [AG027453, NS078758, GM103369]
  2. ASPET Dalton-Zannoni
  3. Dept. of Pharmacology & Chemical Biology, University of Pittsburgh, School of Medicine

Ask authors/readers for more resources

Endogenous mitochondrial genes encode critical oxidative phosphorylation components and their mutation results in a set of disorders known collectively as mitochondrial encephalomyopathies. There is intensive interest in modulating mitochondrial function as organelle dysfunction has been associated with numerous disease states. Proteins encoded by the mitochondrial genome cannot be genetically manipulated by current techniques. Here we report the development of a mitochondrial-targeted RNA expression system (mtTRES) utilizing distinct non-coding leader sequences (NCLs) and enabling in vivo expression of small mitochondrial-targeted RNAs. mtTRES expressing small chimeric antisense RNAs was used as translational inhibitors (TLIs) to target endogenous mitochondrial protein expression in vivo. By utilizing chimeric antisense RNA we successfully modulate expression of two mitochondrially-encoded proteins, ATP6 and COXII, and demonstrate the utility of this system in vivo and in human cells. This technique has important and obvious research and clinical implications. (C) 2014 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available